Literature DB >> 14764777

Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly.

Omar Serri1, Catherine Beauregard, Jules Hardy.   

Abstract

UNLABELLED: Assessment of postoperative disease activity of acromegaly is a major challenge. The consensus criteria for cure, which are glucose-suppressed GH less than 1 micro g/liter and normal IGF-I levels, might be discrepant, and their respective relationship to acromegaly-related morbidity is not well known. THE AIMS OF OUR STUDY WERE: firstly, to correlate plasma IGF-I with plasma glucose-suppressed GH concentrations; and secondly, to correlate each of these biochemical parameters with morbidity [impaired glucose tolerance (IGT), diabetes, and hypertension] in postoperative patients with acromegaly. Fifty-three patients with long-term follow-up (mean, 12.7 yr; range, 1-30 yr) after transsphenoidal surgery for acromegaly and 20 healthy subjects matched for age, sex, and body mass index were evaluated for plasma glucose [by 75-g oral glucose tolerance test (OGTT)], GH (by immunoradiometric assay), plasma IGF-I (by immunoradiometric assay), and blood pressure (BP) measurements. Remission was defined by a normal IGF-I. We identified 34 acromegalics in remission and 19 with active disease. There was no statistical difference between all three groups for age, sex, BMI, and for fasting and 2-h post-OGTT plasma glucose. The time elapsed since surgery was similar in both groups of acromegalics. The OGTT-GH nadir was less than 1 micro g/liter in 31 patients in remission (91.2%) and in nine patients with active disease (47.4%). Prevalence of IGT was lower in acromegalics in remission (14.7%) in comparison with patients with active disease (47.4%; P = 0.01). Plasma IGF-I and GH nadir cut-off of 0.25 microg/liter were strong predictors of abnormal glucose tolerance (odds ratio, 13.6; confidence interval, 2.5-73.7; P = 0.003). GH nadir cut-off of 1 microg/liter and basal GH of 2.5 microg/liter failed to predict abnormal glucose tolerance. There was no statistical difference for prevalence of hypertension and systolic BP values, but diastolic BP was significantly lower in patients in remission than in those with active disease (P < 0.05). Our observations indicate that the validity of the GH threshold of 1 microg/liter post OGTT might be inadequate as a criterion of biochemical remission of acromegaly and as a marker of associated comorbidities. However, normalized IGF-I concentrations and a lower GH cut-off value less than 0.25 micro g/liter are strongly associated with a lower prevalence of IGT and lower diastolic BP in long-term postoperative acromegaly.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14764777     DOI: 10.1210/jc.2003-030915

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  14 in total

1.  Prospective study of surgical treatment of acromegaly: effects on ghrelin, weight, adiposity, and markers of CV risk.

Authors:  Carlos Reyes-Vidal; Jean Carlos Fernandez; Jeffrey N Bruce; Celina Crisman; Irene M Conwell; Jane Kostadinov; Eliza B Geer; Kalmon D Post; Pamela U Freda
Journal:  J Clin Endocrinol Metab       Date:  2014-08-19       Impact factor: 5.958

Review 2.  Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR.

Authors:  Susan L Samson
Journal:  Drugs       Date:  2016-09       Impact factor: 9.546

Review 3.  Update on the medical management of pituitary adenomas.

Authors:  Cheryl A Pickett
Journal:  Curr Neurol Neurosci Rep       Date:  2005-05       Impact factor: 5.081

4.  Growth hormone values after an oral glucose load do not add clinically useful information in patients with acromegaly on long-term somatostatin receptor ligand treatment.

Authors:  Giuseppe Reimondo; Marta Bondanelli; Maria Rosaria Ambrosio; Franco Grimaldi; Barbara Zaggia; Maria Chiara Zatelli; Barbara Allasino; Federica Laino; Emiliano Aroasio; Angela Termine; Pierantonio Conton; Agostino Paoletta; Ernesto Demenis; Ettore Degli Uberti; Massimo Terzolo
Journal:  Endocrine       Date:  2013-06-21       Impact factor: 3.633

5.  Clinical and biochemical characteristics of acromegalic patients with different abnormalities in glucose metabolism.

Authors:  Ana Laura Espinosa-de-los-Monteros; Baldomero González; Guadalupe Vargas; Ernesto Sosa; Moisés Mercado
Journal:  Pituitary       Date:  2011-09       Impact factor: 4.107

Review 6.  Acromegaly.

Authors:  Massimo Scacchi; Francesco Cavagnini
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

7.  Treatment of acromegaly with SS analogues: should GH and IGF-I target levels be lowered to assert a tight control of the disease?

Authors:  R Cozzi; R Attanasio; S Grottoli; G Pagani; P Loli; V Gasco; A M Pedroncelli; M Montini; E Ghigo
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

8.  Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients.

Authors:  Orsalia Alexopoulou; Marie Bex; Peter Kamenicky; Augustine Bessomo Mvoula; Philippe Chanson; Dominique Maiter
Journal:  Pituitary       Date:  2014-02       Impact factor: 4.107

Review 9.  Current diagnosis of acromegaly.

Authors:  Rocio A Cordero; Ariel L Barkan
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

Review 10.  Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant?

Authors:  Pamela U Freda
Journal:  Clin Endocrinol (Oxf)       Date:  2009-02-18       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.